Related Experiment Videos
Hormonal responses to fenfluramine in depressive subtypes
P Mitchell1, G Smythe, G Parker
1School of Psychiatry, University of New South Wales, Sydney.
Summary
This study found that patients with endogenous depression show a reduced prolactin response to fenfluramine, indicating distinct central neurotransmitter function differences between depressive subtypes. These findings highlight variations in brain serotonin pathways in melancholia.
Area of Science:
- Neuroscience
- Psychiatry
- Endocrinology
Background:
- Major depressive disorder (MDD) is heterogeneous, with subtypes potentially exhibiting distinct neurobiological underpinnings.
- Central neurotransmitter systems, particularly serotonin, are implicated in mood regulation and depression pathophysiology.
Purpose of the Study:
- To investigate differences in central neurotransmitter function between endogenous (melancholic) and non-endogenous depression subtypes.
- To examine the serum cortisol and prolactin responses to fenfluramine, a serotonin agonist, in patients with MDD.
Main Methods:
- Thirty subjects diagnosed with major depression were administered 60 mg of oral fenfluramine.
- Serum cortisol and prolactin levels were measured to assess responses to fenfluramine.
- Patients were classified into endogenous and non-endogenous subtypes based on established diagnostic criteria (ICD-9, DSM-III, RDC, Newcastle scale).
Main Results:
- Patients with endogenous depression exhibited a significantly reduced prolactin response to fenfluramine compared to non-endogenous subjects.
- This reduced prolactin response in endogenous depression was independent of baseline prolactin or cortisol levels.
- Basal prolactin levels were lower in bipolar versus unipolar depression and in delusional versus non-delusional patients, but fenfluramine response did not differ between these subgroups.
- Neither basal cortisol levels nor cortisol response to fenfluramine differentiated between depressive subtypes.
Conclusions:
- The study provides evidence for distinct central neurotransmitter function, specifically involving serotonin pathways, in endogenous versus non-endogenous subtypes of depression.
- These neuroendocrine differences suggest a biological basis for differentiating depressive subtypes, potentially aiding in targeted treatment strategies.
- Fenfluramine-induced prolactin response serves as a potential biomarker for identifying neurobiological variations within major depression.